FDA has approved cemdisiran (Livsayis) for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive, Alnylam Pharmaceuticals announced on November 19, 2026.¹ Discovered by Alnylam and developed and commercialized by Regeneron, cemdisiran is the first RNA interference (RNAi) therapeutic approved for gMG and the seventh Alnylam-discovered RNAi therapeutic to win FDA approval in less than 9 years.¹
Key facts
- Drug: cemdisiran (Livsayis; Alnylam, Regeneron)
- Class: RNAi therapeutic (siRNA) silencing complement component 5
- Indication: Adults with AChR antibody-positive generalized myasthenia gravis
- Administration: Subcutaneous, 4 times a year
- Trial: NIMBLE; phase 3, double-blind, placebo-controlled
- Primary end point: MG-ADL placebo-adjusted difference -2.30 at week 24 (p=0.0005)
- Key secondary: QMG placebo-adjusted difference -2.77 (p=0.0015)
- Approval: FDA, announced November 19, 2026; first RNAi therapy for gMG
- Alnylam economics: $25 million approval payment; tiered royalties up to 15%
“Livsayis began with Alnylam science, and its approval demonstrates how our innovation can ultimately reach patients through both our own portfolio and strategic partnerships,” said Yvonne Greenstreet, MD, CEO of Alnylam, in a company press release.¹
How does cemdisiran work for myasthenia gravis?
In AChR antibody-positive gMG, activation of the complement system contributes to damage at the neuromuscular junction.¹ Cemdisiran is a small interfering RNA (siRNA) medicine designed to reduce production of complement component 5 (C5) by silencing the messenger RNA that encodes the protein.¹ It is administered subcutaneously 4 times a year.¹
That mechanism sets cemdisiran apart from the antibody-based C5 inhibitors used in gMG, which bind the C5 protein itself rather than suppressing its production. The FDA approved one such therapy, the dual-binding nanobody gefurulimab (Klygefa), for AChR antibody-positive gMG earlier in November 2026.²
What are the results of the NIMBLE trial for cemdisiran?
The NIMBLE trial, published in The Lancet in May 2026, was a double-blind, randomized, placebo-controlled phase 3 study in adults with generalized myasthenia gravis.³ Cemdisiran 600 mg given subcutaneously every 12 weeks produced a placebo-adjusted difference of -2.30 in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score at week 24, the primary end point (p=0.0005; n=64 vs 59 for placebo).⁴ Mean MG-ADL change was -4.52 with cemdisiran and -2.22 with placebo.⁴ On the Quantitative Myasthenia Gravis (QMG) scale, a key secondary end point, the placebo-adjusted difference was -2.77 (p=0.0015), with mean changes of -4.24 and -1.46.⁴ The trial also tested a fixed-dose combination of cemdisiran and pozelimab given every 4 weeks, which showed a placebo-adjusted MG-ADL difference of -1.74 (p=0.0086); the published results report no additional benefit from adding pozelimab.³,⁴